Alector (ALEC) Competitors $1.39 +0.01 (+0.72%) As of 09:03 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALEC vs. ORIC, PHAR, IMTX, VERV, PGEN, AUTL, MAZE, TYRA, ANAB, and OPTShould you be buying Alector stock or one of its competitors? The main competitors of Alector include ORIC Pharmaceuticals (ORIC), Pharming Group (PHAR), Immatics (IMTX), Verve Therapeutics (VERV), Precigen (PGEN), Autolus Therapeutics (AUTL), Maze Therapeutics (MAZE), Tyra Biosciences (TYRA), AnaptysBio (ANAB), and Opthea (OPT). These companies are all part of the "pharmaceutical products" industry. Alector vs. ORIC Pharmaceuticals Pharming Group Immatics Verve Therapeutics Precigen Autolus Therapeutics Maze Therapeutics Tyra Biosciences AnaptysBio Opthea ORIC Pharmaceuticals (NASDAQ:ORIC) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking. Which has preferable valuation & earnings, ORIC or ALEC? ORIC Pharmaceuticals has higher earnings, but lower revenue than Alector. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioORIC PharmaceuticalsN/AN/A-$100.70M-$1.82-4.35Alector$100.56M1.36-$130.39M-$1.23-1.12 Does the MarketBeat Community prefer ORIC or ALEC? Alector received 85 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 74.74% of users gave ORIC Pharmaceuticals an outperform vote while only 60.94% of users gave Alector an outperform vote. CompanyUnderperformOutperformORIC PharmaceuticalsOutperform Votes7174.74% Underperform Votes2425.26% AlectorOutperform Votes15660.94% Underperform Votes10039.06% Which has more risk & volatility, ORIC or ALEC? ORIC Pharmaceuticals has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Do analysts rate ORIC or ALEC? ORIC Pharmaceuticals presently has a consensus price target of $18.86, indicating a potential upside of 138.40%. Alector has a consensus price target of $3.50, indicating a potential upside of 153.62%. Given Alector's higher possible upside, analysts plainly believe Alector is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14 Is ORIC or ALEC more profitable? ORIC Pharmaceuticals has a net margin of 0.00% compared to Alector's net margin of -257.54%. ORIC Pharmaceuticals' return on equity of -44.54% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets ORIC PharmaceuticalsN/A -44.54% -40.72% Alector -257.54%-108.77%-27.03% Does the media refer more to ORIC or ALEC? In the previous week, Alector had 1 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 2 mentions for Alector and 1 mentions for ORIC Pharmaceuticals. ORIC Pharmaceuticals' average media sentiment score of 1.89 beat Alector's score of 0.43 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment ORIC Pharmaceuticals Very Positive Alector Neutral Do institutionals & insiders have more ownership in ORIC or ALEC? 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 9.1% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryORIC Pharmaceuticals beats Alector on 9 of the 17 factors compared between the two stocks. Remove Ads Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$136.74M$3.11B$5.73B$8.15BDividend YieldN/A1.46%4.41%4.09%P/E Ratio-0.8128.6224.0519.22Price / Sales1.36436.44416.1090.05Price / CashN/A168.6838.0534.64Price / Book0.983.456.934.38Net Income-$130.39M-$71.72M$3.18B$246.90M7 Day Performance-0.72%1.95%10.25%4.31%1 Month Performance-18.82%-12.26%0.89%-7.71%1 Year Performance-77.45%-21.54%14.64%5.72% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector3.7434 of 5 stars$1.39+0.7%$3.50+151.8%-77.5%$137.73M$100.56M-0.82270ORICORIC Pharmaceuticals4.2139 of 5 stars$7.63-4.6%$18.86+147.1%-47.6%$541.94MN/A-4.1980Gap DownPHARPharming Group2.7035 of 5 stars$7.96-1.1%$27.00+239.2%-22.6%$541.53M$285.75M-30.62280Earnings ReportIMTXImmatics2.1051 of 5 stars$4.50-3.4%$16.67+270.4%-58.5%$537.10M$115.50M-6.82260Upcoming EarningsNews CoverageVERVVerve Therapeutics2.0553 of 5 stars$5.95-11.3%$25.50+328.6%-54.2%$528.34M$32.33M-2.42110PGENPrecigen3.5502 of 5 stars$1.77-4.8%$7.00+295.5%+24.5%$518.38M$3.96M-3.22190AUTLAutolus Therapeutics3.1628 of 5 stars$1.94-3.5%$10.40+436.1%-68.7%$516.22M$10.09M-1.60330Upcoming EarningsGap DownMAZEMaze TherapeuticsN/A$11.78-1.8%$25.67+117.9%N/A$515.69M$167.50M0.00121TYRATyra Biosciences1.7683 of 5 stars$10.16-7.1%$30.50+200.2%-38.6%$514.13MN/A-6.3120High Trading VolumeANABAnaptysBio3.6738 of 5 stars$16.73+2.4%$35.11+109.9%-29.6%$513.06M$91.28M-2.75100Positive NewsOPTOpthea2.0148 of 5 stars$3.24-7.7%$12.00+270.4%-1.3%$498.67M$87,666.000.008Gap Up Remove Ads Related Companies and Tools Related Companies ORIC Pharmaceuticals Alternatives Pharming Group Alternatives Immatics Alternatives Verve Therapeutics Alternatives Precigen Alternatives Autolus Therapeutics Alternatives Maze Therapeutics Alternatives Tyra Biosciences Alternatives AnaptysBio Alternatives Opthea Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 3/18/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored92% win rate – even whe the market crashesMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredMarch 18th: Gold SHOCK?Starting March 18th, a major shift could send gold soaring — or crashing. Either way this shift goes... ...InvestorPlace | SponsoredThe $20 trillion wealth secret of room 3330In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
